Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment
European Journal of Neurology2020Vol. 27(6), pp. 1066–1075
Citations Over TimeTop 10% of 2020 papers
Viktor von Wyl, Bernhard F. Décard, Pascal Benkert, Johannes Lorscheider, Peter Hänni, Carmen Lienert, Jens Kühle, Tobias Derfuß, Ludwig Kappos, Özgür Yaldizli
Abstract
Age is an important factor independently affecting clinical outcomes in MS. This should be considered when designing clinical trials or choosing DMT.
Related Papers
- → Experimental In Vivo Models of Multiple Sclerosis: State of the Art(2017)24 cited
- → Erythrocyte membrane fatty acids in patients with multiple sclerosis(2009)19 cited
- → What Is Multiple Sclerosis?(2019)6 cited
- → Is the optic-spinal form of multiple sclerosis comparable to typical multiple sclerosis?(2000)
- → Role of Plasma MicroRNAs 145 and 484 in Diagnosis of Multiple Sclerosis, Disease Activity and the Transition from Relapsing Remitting Multiple Sclerosis to Secondary Progressive Multiple Sclerosis(2023)